Chronic obstructive pulmonary disease (COPD) is a severe respiratory condition associated with a markedly increased risk of lung cancer (LC), which develops in 10–30% of COPD patients. Currently, no validated criteria exist for stratifying COPD clinical phenotypes according to their risk of malignant transformation. A major limitation in addressing this issue is the restricted accessibility of biological material from precancerous bronchial epithelial lesions in patients. This pilot study aimed to investigate the methylation profile of microRNA genes associated with precancerous changes in peripheral blood of individuals with COPD, as a potential non-invasive approach for risk assessment. We assessed the methylation levels of six microRNA genes (MIR492, MIR650, MIR487A, MIR6132, MIR1202, and MIR634) in the peripheral blood mononuclear cells obtained from the COPD patients. Targeted bisulfite massively parallel sequencing was performed on the SurfSeq 5000 platform (paired-end, 2 × 150 bp). Statistical analysis revealed significant differences in methylation levels at specific CpG sites between healthy controls and COPD patients: for MIR487A (position_id:chr14:101051905+, p = 0.001) and for MIR650 (position_id: chr22:22822637+, p = 0.012). Additionally, a trend towards significance was observed for MIR6132 (position_id:chr7:117019932+, p = 0.070). These findings suggest that the methylation status of MIR487A and MIR650 may serve as potential epigenetic markers for identifying individuals with COPD at higher risk of precancerous transformation. Further validation in larger cohorts is warranted to confirm their clinical utility.